(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.

Stress isn’t just bad for you — it’s also bad for your employer. Factoring in absenteeism, diminished productivity, turnover, ...

Diabetic students often have glucose monitors connected to phone apps that sound an alarm when they detect a problem, but ...

Monitoring of the body's blood sugar is essential to the treatment of diabetes. But getting effective glucose readings has long been a challenge, according to UW Medicines Diabetes Institute professor ...

I had the opportunity to try out a commercial continuous glucose monitor. This device was attached to the back of my arm and ...

Glucose monitoring without piercing the skin is a prize companies like Apple and Samsung have been aiming for. Now, Samsung ...

The FDA has previously issued warnings about unauthorized wearables claiming to measure blood glucose levels, so it's super ...

RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and ...